Denmark’s Novo Nordisk is launching an ultra-thin, ultra-short universal pen needle that aims to make injections more comfortable for patients with diabetes. Canada is the first country to make NovoFine® Plus available and will be followed by several other countries during 2014 and 2015.

NovoFine Plus is as thin as two human hairs and 4 millimetre long, and its thinness and length are associated with less pain and less risk of intramuscular injection. The new needle will facilitate type 2 diabetes patients, who are often reluctant towards initiating insulin therapy, that consider needle anxiety a common barrier to initiation.

“We know needle anxiety can be a real barrier when people with diabetes start insulin therapy, and in some people this fear really compromises their treatment. As part of our broad portfolio within treatment, devices and needles, we are pleased to provide this new option to people with diabetes,” says Jesper Klove, Senior Vice President, Device R&D at Novo Nordisk.

NovoFine could prove to be a major relief for diabetes patients in the Middle East & North Africa (MENA) region. Almost 11 per cent of the region’s total population of 375 million now has diabetes, and according to the International Diabetes Federation (IDF), by 2030 the number of people with diabetes in the region is expected to rise to 59.7 million from 32.8 million in 2013 (http://scandinaviamideast.com/diabetes-in-mena-opportunity-for-scandinavian-healthcare-providers/).

NovoFine offers patients faster injections that need less force, is compatible with all major pen devices and has been designed to reduce the risk of bending or breakage.